{"id":"ilaprazole-amoxicillin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash (amoxicillin-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ilaprazole is a proton pump inhibitor that blocks the H+/K+-ATPase enzyme in gastric parietal cells, reducing stomach acid production and creating an environment where amoxicillin can effectively eliminate H. pylori. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis. This combination therapy addresses both the acid-related damage and the underlying bacterial infection responsible for most peptic ulcers.","oneSentence":"Ilaprazole inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection and healing peptic ulcers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:12.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT05410223","phase":"NA","title":"Efficacy and Safety Study of Egg Yolk Antibody in Adjuvant Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2021-04-06","conditions":"Helicobacter Pylori Infection","enrollment":100},{"nctId":"NCT05455372","phase":"NA","title":"Influence of Oral Hp Infection and Oral Related Factors on Gastric Hp Infection and Eradication Therapy","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2022-07-08","conditions":"Helicobacter Pylori Infection","enrollment":600},{"nctId":"NCT03342456","phase":"PHASE4","title":"The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2017-12-13","conditions":"Duodenal Ulcer Due to Helicobacter Pylori","enrollment":184},{"nctId":"NCT02648659","phase":"PHASE4","title":"The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2016-03-02","conditions":"Peptic Ulcer","enrollment":50},{"nctId":"NCT03362281","phase":"PHASE3","title":"Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-10","conditions":"Peptic Ulcer Hemorrhage","enrollment":540},{"nctId":"NCT03139253","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Yanqing Li","startDate":"2017-05-30","conditions":"Antimicrobial Susceptibility Testing, Triple Therapy","enrollment":120},{"nctId":"NCT02988089","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2017-04-20","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":480},{"nctId":"NCT03099876","phase":"","title":"A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients","status":"UNKNOWN","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2017-03-01","conditions":"Helicobacter Pylori Infection","enrollment":320},{"nctId":"NCT02998437","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2016-12","conditions":"Drug Interaction Potentiation","enrollment":28},{"nctId":"NCT02873065","phase":"PHASE4","title":"Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-09","conditions":"Helicobacter Pylori Eradication","enrollment":""},{"nctId":"NCT02835560","phase":"PHASE4","title":"Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2013-06","conditions":"Helicobacter Pylori Eradication Antibiotic","enrollment":100},{"nctId":"NCT02401477","phase":"PHASE4","title":"Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2014-12","conditions":"Helicobacter Infections","enrollment":90},{"nctId":"NCT02352701","phase":"","title":"Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2012-12","conditions":"Helicobacter Infections","enrollment":320},{"nctId":"NCT02084420","phase":"PHASE3","title":"Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2012-12","conditions":"Peptic Ulcer","enrollment":323}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ilaprazole","Amoxicillin"],"phase":"marketed","status":"active","brandName":"Ilaprazole + Amoxicillin","genericName":"Ilaprazole + Amoxicillin","companyName":"Il-Yang Pharm. Co., Ltd.","companyId":"il-yang-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ilaprazole is a small molecule used in combination with Amoxicillin, a sodium salt of the antibiotic amoxicillin, to treat conditions such as Helicobacter Pylori infection and peptic ulcer hemorrhage. This combination is also being studied for its potential to potentiate drug interactions and for its safety profile when used with other medications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}